The British Horseracing Authority (BHA) would like to advise the Responsible Person (i.e. trainers, owners, breeders) and their veterinary surgeons of a new Rule requiring a mandatory 30 day Stand-Down period from racing following the administration of any bisphosphonate licensed for equine use. This Rule will be effective from 10 August 2017.

The Rule, an addition to Schedule (B)3 – Requirements for horse to run, will read as follows:

Due to their complex nature and action, the excretion of bisphosphonates may be unpredictable, leading to considerable variation in excretion times.  This variability may be increased when bisphosphonates are administered to horses with on-going musculoskeletal disease process, including the possibility that bisphosphonates may be released from bone at a period remote from initial administration. As such, it cannot be guaranteed that future musculoskeletal disease processes will not result in an Adverse Analytical Finding.

As a guide, the BHA are aware of data from studies in normal horses which indicate that if a single dose of Tildren® (CEVA) at 1 mg/kg were administered intravenously, the Detection Time would be unlikely to exceed the Stand-Down period. A discussion between the Responsible Person and their veterinary surgeon is essential when considering administration of any medication which is a Prohibited Substance on raceday.